
AYLA
US listing · $7.9M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · -46.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 3, 2022 | After the close | -0.49 | -0.66 | -34.7% |
| Aug 15, 2022 | After the close | -0.65 | -0.54 | +16.9% |
| May 16, 2022 | After the close | -0.68 | -0.66 | +2.9% |
| Mar 28, 2022 | Before the open | -0.61 | -0.66 | -8.2% |
| Nov 15, 2021 | Before the open | -0.80 | -0.68 | +15.0% |
| Aug 12, 2021 | After the close | -0.63 | -0.75 | -19.0% |
| May 14, 2021 | Before the open | -0.71 | -0.74 | -4.2% |
| Mar 24, 2021 | After the close | -0.58 | -0.73 | -25.9% |
| Nov 16, 2020 | After the close | -0.55 | -0.59 | -7.3% |
| Aug 13, 2020 | Before the open | -0.53 | -0.74 | -39.6% |
| Jun 22, 2020 | Before the open | -0.76 | -1.32 | -73.7% |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic…